Enveric Biosciences, Inc. – NASDAQ:ENVB

Add to watchlist

$1.16

+0.81

+234.29%

Market closed

Open in about 11 hours

-32.78%

month

-32.78%

quarter

-73.36%

year

Market Cap	3.17M
Enterprise value	N/A

P/E	-0.12
EV/Sales	N/A
EV/EBITDA	0.36
Price/Sales	N/A
Price/Book	0.10
PEG ratio	N/A
EPS	-6.39

Revenue	N/A
EBITDA	-12.47M
Income	-15.07M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Enveric Biosciences, Inc. (NASDAQ:ENVB): Profit margin
Jun 2023	0	-6.36M
Sep 2023	0	-2.82M
Dec 2023	647.09K	-3.43M	-530.98%
Mar 2024	0	-2.45M

Enveric Biosciences Financials Estimate

Q Y

Enveric Biosciences, Inc. (NASDAQ:ENVB): Analyst Estimates
Mar 2024	0	-2.45M
Sep 2025	0	-822.08K
Oct 2025	0	-1.44M
Dec 2025	0	-1.36M

Analysts Price target
Financials & Ratios estimates

Enveric Biosciences, Inc. (NASDAQ:ENVB): Earnings per share (EPS)
2023-05-11	-0.75	-0.75

Enveric Biosciences, Inc. (NASDAQ:ENVB): Debt to assets
Jun 2023	9800170	4.92M	50.26%
Sep 2023	6619194	4.18M	63.2%
Dec 2023	6117480	2.34M	38.31%
Mar 2024	8849794	2.36M	26.76%

Enveric Biosciences, Inc. (NASDAQ:ENVB): Cash Flow
Jun 2023	-4.46M	16.85K	-1.05M
Sep 2023	-2.74M	20	-105K
Dec 2023	-1.75M	-38	-186.08K
Mar 2024	-2.59M	0	6.65M

Enveric Biosciences alternative data

Enveric Biosciences, Inc. (NASDAQ:ENVB): Employee count
Aug 2023	25
Sep 2023	25
Oct 2023	25
Nov 2023	25
Dec 2023	25
Jan 2024	25
Feb 2024	25
Mar 2024	25
Apr 2024	25
May 2024	7
Jun 2024	7
Jul 2024	7

Enveric Biosciences
Hedge Funds Holdings Q1 2023

100.00% 0.00%

of ENVB is owned by hedge funds

9 -1

hedge funds hold ENVB stock

203.27K +30.35K

shares is hold by hedge funds

ENVB hedge funds holdings changes

Enveric Biosciences
Insider Trading

Enveric Biosciences, Inc. (NASDAQ:ENVB): Insider trades (number of shares)
Period	Buy	Sel
Sep 2023	1000	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	15 Sep 2023	PASQUALONE FRANK director director	Common Stock	1,000	$2.14	$2,140
Sale	16 Nov 2018	SIKARIA FAMILY 2008 REVOCABLE TRUST DATED 02/28/2008	Common Stock	98,150	$0.3	$29,249
Sale	16 Nov 2018	LOKESH SIKARIA TRUST DATED 12/14/2012	Common Stock	100,000	$0.3	$29,800
Sale	16 Nov 2018	SIKARIA CHANDA	Common Stock	100,000	$0.3	$29,800
Sale	16 Nov 2018	SIKARIA LOKESH	Common Stock	100,000	$0.3	$29,800
Sale	17 Jul 2018	DEVANUR GIRI	Common stock	100,000	$2.27	$226,600
Purchase	12 Jun 2018	DEVANUR GIRI	Warrant	25,000	$0.27	$6,750
Sale	7 Jun 2018	DEVANUR GIRI	Common stock	329,357	$2.01	$661,349
Option	1 Jan 2018	LANGER ARTHUR M	Common Stock	7,680	N/A	N/A
Option	1 Jan 2018	LANGER ARTHUR M	Restricted Stock Unit	7,680	N/A	N/A

ENVB insider trading transactions

Enveric Biosciences
Executives

Insider	Age	Compensation
Mr. Barry M. Kostiner (1971) Consultant	54	$200,000
Mr. David Ian Johnson (1958) Executive Chairman	67	$100,000
Mr. Avani V. Kanubaddi (1973) Pres & Chief Operating Officer	52	$60,000

Enveric Biosciences
Latest News

Monday, 25 November 2024
09:00	Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior	businesswire.com
Monday, 4 November 2024
10:36	Enveric Biosciences Announces Broad Range of Patent Issuances	businesswire.com
Thursday, 26 September 2024
08:30	Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop	businesswire.com
Wednesday, 25 September 2024
08:30	Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit	businesswire.com
Monday, 12 August 2024
17:30	Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results	businesswire.com
Tuesday, 30 July 2024
07:43	Why Is Enveric Biosciences (ENVB) Stock Up 18% Today?	investorplace.com
Friday, 28 June 2024
08:00	Diamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB)	globenewswire.com
Tuesday, 25 June 2024
08:00	Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate	businesswire.com
Thursday, 30 May 2024
08:00	Enveric Biosciences to Participate in BIO International Convention 2024	businesswire.com
Wednesday, 15 May 2024
06:00	Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results	businesswire.com
Tuesday, 14 May 2024
10:35	Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders	accesswire.com
08:00	Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders	businesswire.com
Wednesday, 8 May 2024
07:00	Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids	businesswire.com
Thursday, 2 May 2024
18:51	Enveric Biosciences, Inc. (ENVB) Stock Falls Amid Market Uptick: What Investors Need to Know	Zacks Investment Research
Friday, 26 April 2024
18:56	Enveric Biosciences, Inc. (ENVB) Stock Declines While Market Improves: Some Information for Investors	Zacks Investment Research
Wednesday, 17 April 2024
08:30	New Strong Buy Stocks for April 17th	Zacks Investment Research
Friday, 12 April 2024
13:01	What Makes Enveric Biosciences (ENVB) a New Strong Buy Stock	Zacks Investment Research
08:32	New Strong Buy Stocks for April 12th	Zacks Investment Research
Thursday, 29 February 2024
14:04	Why Is Enveric Biosciences (ENVB) Stock Up 120% Today?	InvestorPlace
Wednesday, 20 December 2023
11:16	Bears are Losing Control Over Enveric Biosciences, Inc. (ENVB), Here's Why It's a 'Buy' Now	Zacks Investment Research
09:01	5 Biotech stocks tapping into unmet mental health treatment needs	MarketBeat
Friday, 19 May 2023
06:00	How to Develop a Penny Stocks Trading Mentality	PennyStocks
Thursday, 18 May 2023
15:06	Why Is Enveric Biosciences (ENVB) Stock Up 120% Today?	InvestorPlace
Wednesday, 22 February 2023
07:33	Enveric Biosciences to Present at the Gravitas Securities Inc. 6th Annual Growth Conference	Business Wire
Sunday, 5 February 2023
14:30	The 7 Most Promising Psychedelic Stocks to Buy in February	InvestorPlace
Wednesday, 1 February 2023
07:33	Enveric Biosciences to Present at the BIO CEO & Investor Conference	Business Wire
Wednesday, 21 December 2022
07:30	Enveric Biosciences to Present at the 6th Annual Neuroscience Innovation Forum and Biotech Showcase during "J.P. Morgan Health Care Week 2023"	Business Wire
Wednesday, 31 August 2022
07:30	Enveric Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022	Business Wire
Tuesday, 30 August 2022
15:02	7 Psychedelics Stocks to Buy for a Big Drug Boom	InvestorPlace
Tuesday, 16 August 2022
16:28	7 Short-Squeeze Stocks to Put on Your Must-Watch List	InvestorPlace

Frequently Asked Questions (FAQ)

What's the price of Enveric Biosciences stock today?

One share of Enveric Biosciences stock can currently be purchased for approximately $1.16.
When is Enveric Biosciences's next earnings date?

Unfortunately, Enveric Biosciences's (ENVB) next earnings date is currently unknown.
Does Enveric Biosciences pay dividends?

No, Enveric Biosciences does not pay dividends.
How much money does Enveric Biosciences make?

Enveric Biosciences has a market capitalization of 3.17M. Enveric Biosciences made a loss 17.29K US dollars in net income (profit) last year or -$0.75 on an earnings per share basis.
What is Enveric Biosciences's stock symbol?

Enveric Biosciences, Inc. is traded on the NASDAQ under the ticker symbol "ENVB".
What is Enveric Biosciences's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Enveric Biosciences?

Shares of Enveric Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Enveric Biosciences's key executives?
Enveric Biosciences's management team includes the following people:
- Mr. Barry M. Kostiner Consultant(age: 54, pay: $200,000)
- Mr. David Ian Johnson Executive Chairman(age: 67, pay: $100,000)
- Mr. Avani V. Kanubaddi Pres & Chief Operating Officer(age: 52, pay: $60,000)
How many employees does Enveric Biosciences have?

As Jul 2024, Enveric Biosciences employs 7 workers, which is 72% less then previous quarter.
When Enveric Biosciences went public?

Enveric Biosciences, Inc. is publicly traded company for more then 10 years since IPO on 4 May 2015.
What is Enveric Biosciences's official website?

The official website for Enveric Biosciences is enveric.com.
Where are Enveric Biosciences's headquarters?

Enveric Biosciences is headquartered at 4851 Tamiami Trail North, Naples, FL.
How can i contact Enveric Biosciences?

Enveric Biosciences's mailing address is 4851 Tamiami Trail North, Naples, FL and company can be reached via phone at +239 3021707.

Enveric Biosciences, Inc.

enveric.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

+239 3021707

4851 Tamiami Trail North
Naples, FL 34103

CIK: 0000890821
ISIN: US29405E2081
CUSIP: 29405E208